Obstet Gynecol Sci Search

CLOSE


Obstet Gynecol Sci > Volume 60(1); 2017 > Article
Kim, Jang, Chang, Sung, Lee, Lee, Choi, Oh, Roh, and Kim: Clinical outcomes and neurodevelopmental outcome of prenatally diagnosed agenesis of corpus callosum in single center of Korea

Abstract

Objective

With recent advances and frequent use of prenatal ultrasound, the antenatal diagnosis of agenesis of the corpus callosum (ACC) is not rare in obstetrics practices. However, information regarding the long-term neurological outcome remains uncertain. The aim of this study was to investigate clinical outcomes of prenatally diagnosed ACC and to analyze postnatal neurodevelopmental outcomes of ACC neonates born in our single center.

Methods

We retrospectively reviewed 56 cases of prenatally suspected ACC referred to our center.

Results

Fifty-six fetuses were diagnosed with ACC, and 12 of those were followed-up in our center until delivery. Of the remaining 44, 7 were delivered after being referred back to the original hospital, 23 were lost to follow-up, and 14 had unknown outcomes. Among all 56, 29 were considered to have isolated ACC and 27 were considered to have non-isolated ACC. Of the 10 live fetuses delivered in our center, four had isolated ACC, three had non-isolated ACC, and the rest had outcomes unrelated to ACC. Neurodevelopmental outcome was followed-up until approximately age 3 years. Of the four with isolated ACC, three (75%) had normal neurodevelopmental outcomes.

Conclusion

Similar to other studies, the results of our single-center study included positive neurodevelopmental outcomes for those with isolated ACC. However, despite our endeavor to counsel patients with prenatally diagnosed ACC, the delivery rate in our center was quite low. Therefore, larger, multicenter, retrospective studies including long-term neurological development outcomes are crucial and urgently needed to provide better counseling.

Introduction

The corpus callosum connects two interhemispheres [1], and agenesis of corpus callosum (ACC) is the most common central nervous system defect [2]. ACC has been reported in 0.3% to 0.7% of the general population and in 2% to 3% of those with developmentally retarded [3,4,5]. It may be either complete or partial [6]; the partial form of ACC is also called hypogenesis [7] of corpus callosum. If there are no other anomalies accompanying ACC, then it is defined as isolated ACC.
Since the 1990s, ACC has been diagnosed prenatally through ultrasound screening [8]. Prenatal diagnosis of ACC is considered important because it may be associated with central nervous system abnormalities [9,10] such as mental retardation, epilepsy, cerebral palsy, and others [11,12]. If other anomalies are combined with non-isolated ACC, then outcomes, especially those regarding neurodevelopment, are usually poor [13]. Thus, termination of pregnancy is sometimes recommended when non-isolated ACC is diagnosed [14]; however, this option varies by country.
Long-term studies, especially those regarding neurodevelopmental outcomes, are not available worldwide. Although there is still much controversy [15], most patients with isolated ACC have had good prognoses [16]. In those with isolated ACC, 72.2% showed normal development [16]; in several small sample studies, 100% showed normal development [17]. Normal or mildly delayed neurodevelopment resolves in 67% of isolated ACC, but in non-isolated ACC only 7% resolves [18]. Therefore, distinguishing isolated ACC from non-isolated ACC is clinically important for prenatal counseling.
Few studies have targeted Korean patients regarding the long-term neurodevelopmental outcomes of ACC despite the common practice of targeted ultrasound. Therefore, based on our patients, we aimed to investigate clinical outcomes of prenatally diagnosed ACC and, importantly, to analyze the neurodevelopmental outcomes of those with prenatally diagnosed ACC so that appropriate counseling can be provided.

Materials and methods

We retrospectively reviewed 70 cases of antenatally suspected ACC in fetuses referred to or diagnosed at our center between 2008 and 2015. We excluded 14 patients (20%) with suspected ACC diagnosed at a referral hospital. Thus, only 56 fetuses (80%) with suspected ACC examined at our center were included in this study. Among these, 53 were referred to our center due to abnormal findings on ultrasonography performed at a referral hospital and three were followed-up at our center. The study was approved by the institutional review board.
We investigated the following data for each patient: gestational age and ultrasonography findings at the time of referral or first diagnosis of ACC including ventriculomegaly and tear-drop sign; karyotype result if performed; brain ultrasound or magnetic resonance imaging (MRI) findings before or after birth; neonatal outcome; postnatal diagnosis; delivery mode; delivery indication; gestation age at delivery; neonatal birth weight; and neonatal intensive care unit admission. Gestation age at diagnosis was recorded based on the gestation age at the time of transfer or time of diagnosis in our hospital. The diagnosis of ACC was made by using indirect signs of ACC on ultrasound, including the presence of a tear-drop sign and absence of cavum septum pellucidum (CSP), or by direct nonvisualization of the corpus callosum on the sagittal plane (Fig. 1). Ventriculomegaly, an enlargement of the posterior horn more than 10 mm, was not regarded as an associated anomaly because it may be one of the characteristics of ACC.
Isolated ACC was defined when there was no other anomaly on ultrasound or MRI based on prenatal or postnatal findings, respectively. The partial or complete form of ACC was not separately distinguished because they showed no significant difference with respect to functional subtyping of the callosum and neurological outcome [19].
We analyzed the neurodevelopmental outcomes based on medical records assessed and described by the pediatric neurology or rehabilitation doctors if delivery was performed in our center. Neurodevelopmental outcomes were followed-up until approximately age 3 years. To supplement neurodevelopmental outcomes of isolated ACC, we also tried analyzing neurodevelopmental outcome of postnatally diagnosed ACC patients (n=9) who primarily visited the pediatric neurology or rehabilitation department of our center. We classified neurodevelopmental outcomes into four categories; normal, mild, moderate, severe. ‘Mild’ included children with neurodevelopment delay within six months, ‘Moderate’ with 6 months to 12 months delay, and ‘Severe’ with neurodevelopment delay of more than 12 months. The assessment of neurologic development was performed through the clinical history taking of development milestones. Objective development evaluation includes hand evaluation, Alberta infant motor score, Activities of Daily Living evaluation, Denver Developmental Screening Test, etc. but which were not performed on every child. Follow-up evaluation for all cases with prenatally diagnosed ACC (and postnatally diagnosed ACC) was performed by pediatricians and pediatric neurologists. The final neurodevelopmental outcome was assessed by two pediatric neurologists (JWL and JHL) by review of medical record.
Since we could not obtain results by directly calling the patient, which was not permitted by IRB, we endeavored to ascertain follow-up or delivery results by calling the referral institution if delivery was not performed in our institution. “Follow-up loss” meant that patients did not go back to the original clinic or give birth there. Patients of hospitals that no longer exist or of hospitals that could not provide information were classified as “unknown.” To check whether ACC was present, brain ultrasound was performed after birth. Some patients underwent brain MRI when other brain anomalies were suspected.

Results

This study included 56 patients with ACC prenatally diagnosed by ultrasound examination. Through prenatal diagnosis, we classified 56 patients as having either isolated or non-isolated ACC and summarized the clinical characteristics (Table 1). Among these 56 patients, 29 (51.8%) were considered to have isolated ACC and 27 (48.2%) were considered to have non-isolated ACC. These classifications were based on prenatal sonographic findings alone and did not consider the postnatal diagnosis. Ventriculomegaly and a tear-drop sign were observed in approximately 70% to 80% cases of prenatally diagnosed ACC. The median atrial diameters were 16.3 mm and 12.6 mm for isolated ACC and non-isolated ACC, respectively. Prenatal chromosomal analyses were performed for 6/29 (20.7%) in the isolated ACC group and for 8/27 (29.6%) in the non-isolated ACC group. With the exception of unknown results, all fetuses in the isolated ACC group showed normal chromosomes and one of eight (12.5%) in the non-isolated ACC group had a chromosomal abnormality (trisomy 18). According to follow-up results, the rates of referral back to the hospital were 17.2% for the isolated ACC group and 7.4% for the non-isolated ACC group.
We investigated the follow-up results of these fetuses with prenatally diagnosed ACC (Fig. 2). Twelve deliveries were performed in our center, including two terminations that occurred during the early study period; the other 44 patients were referred back to the original clinic or lost to follow-up. Among 44 patients who did not undergo delivery at our hospital, seven were referred back to the original clinic due to their long distance from our center and were confirmed as having delivered the pregnancy. Twenty-three patients did not go back to the original clinic or did not give birth there and were considered lost to follow-up. This group was suspected of undergoing termination. The remaining 14 patients of no longer existing hospitals or hospitals that could not provide information were classified as unknown. These follow-up data indicate that the overall percentage of follow-up loss for prenatally diagnosed ACC was 41%, but it increased up to 66% when the unknown category was included.
Clinical characteristics and outcomes for 12 fetuses with ACC delivered at our center are presented in Table 2. Among 10 live fetuses delivered, four had isolated ACC, three had non-isolated ACC, and the rest were found to have outcomes unrelated to ACC after birth. Excluding termination cases, three out of four suspected isolated ACC cases during the prenatal period were actually confirmed as isolated ACC postnatally, but the other one was finally diagnosed as non-isolated ACC combined with semilobar to lobar holoprosencephaly. On the contrary, one out of the six cases considered to be non-isolated ACC was finally proven to be isolated ACC because the degree of enlarged mega cisterna magna was found to be normal on postnatal ultrasound. In the non-isolated ACC group, two patients had holoprosencephaly (patients 2 and 7) and one had cleft lip and right inguinal hernia (patient 10). One of two patients had lobar holoprosencephaly, was followed-up for delayed development, and was lost to follow-up after 17 months (patient 2); another had semilobar to lobar holoprosencephaly and is currently being observed for symptomatic localization-related epilepsy (patient 7). Among our study population, there were two patients who were initially suspected with ACC but were subsequently diagnosed as having complications of fetal hydrops and coarctation of the aorta. ACC was originally diagnosed because the CSP was not visible on ultrasound.
Among the four diagnosed with isolated ACC, one was transferred to another hospital because of the mother's personal preference (patient 3). The other three (patients 1, 4, and 6) were followed-up for at least 12 months and showed no developmental delay, suggesting that at least 75% of patients with isolated ACC had normal neurodevelopment.
Table 3 shows the summary of clinical characteristics of 10 live births (with the exception of two terminations). Median gestation age at diagnosis was 27 weeks. However, with the exclusion of four patients admitted for delivery near term or at term, the median gestation age at prenatal diagnosis was 22 weeks. Chromosomal study results were available for 8 of the 10 patients who delivered. Two did not undergo a chromosomal study (patients 1 and 3) because they planned for delivery regardless of abnormal chromosome results of the fetuses. Of these eight who underwent chromosomal study, a normal karyotype was found in seven fetuses and one had chromosomal anomalies: arr Xp11.22(53,166,281-53,427,895)x1 (patient 7). One patient who had a chromosomal abnormality had non-isolated ACC and semilobar to lobar holoprosencephaly and was small for gestational age; this patient later presented with epilepsy.
Supplementary analysis including postnatally diagnosed isolated ACC, in which follow-up was performed at least 9 months to maximum 4 years in the pediatric neurology or rehabilitation department, demonstrated that 5 (55.6%) showed normal developmental outcome, 2 (22.2%) showed mild developmental delay, another 2 (22.2%) showed moderate developmental delay, and none showed severe developmental delay.

Discussion

Our data demonstrated that approximately 75% of isolated ACC showed normal neurodevelopment. Although limited in number, our finding is in line with previous studies reporting that the rate of normal neurodevelopment for 16 patients with isolated ACC was 71.2% [20]. In our study, we also found that the follow-up loss rate for prenatally diagnosed ACC is substantial even for isolated ACC, despite our endeavor to counsel these patients. In fact, each physician in our center generally provides information about normal neurodevelopmental outcomes being more than 80% for isolated ACC based on previous works [17,21]. Therefore, a conundrum beyond proper counseling at the time of prenatal diagnosis of ACC and subsequent follow-up remains in our country. However, the impact of proper counseling for prenatally diagnosed ACC was demonstrated by a study performed in another country. For instance, in France, the termination rate for ACC has decreased by almost 17%, from 13/35 (37.1%) in 2000-2003 to 9/44 (20.5%) in 2003-2006 [22]. This decrease seems to be attributable to proper counseling based on information regarding the good prognosis for isolated ACC. Therefore, although it is difficult to lower the termination rate for non-isolated ACC with associated anomalies, appropriate counseling regarding the higher percentage of normal neurodevelopment for isolated ACC is expected to reduce that termination rate.
When checking brain structures during the mid-trimester fetal anatomy survey, there is a tendency to obtain a mainly transverse view. However, a mid-sagittal view is more accurate for determining ACC. Moreover, indirect signs of ACC are either absent or not clearly visible at the time of mid-trimester screening ultrasonography, which is performed before 24 weeks of gestation in many cases [23]. The gestational age at diagnosis of ACC in other countries is 23 to 26 weeks [24,25], which appears rather late compared to that in our country, although this is probably due to the more frequent use of ultrasound in our country. ACC is frequently associated with ventriculomegaly; our data show that up to 70% to 80% of those with ACC have ventriculomegaly. Therefore, fetuses with ventriculomegaly shown by prenatal ultrasound require a more detailed examination for the existence of the corpus callosum. In fact, it is reported that there is a callosal abnormality in 13% of ventriculomegaly cases [18]. When indirect signs of ACC are suspected on mid-trimester ultrasound screening, short-term follow-up and repeat ultrasound with a mid-sagittal view are recommended.
Sometimes it may be difficult to confirm ACC as being isolated on prenatal ultrasonography alone. Our data also showed that one out of four cases of prenatally diagnosed ACC was subsequently found to be non-isolated after birth. In reality, it was reported that approximately 5% to 20% of cases are misdiagnosed as isolated ACC during the prenatal period [26]. On the contrary, 16% (1/6) of non-isolated ACC cases were finally proven to be isolated ACC, indicating that false-positive diagnoses are possible. To overcome this kind of false-negative or positive diagnosis, differential diagnoses such as septo-optic dysplasia and holoprosencephaly should be considered if there is no CSP on ultrasonography; in addition, some ancillary tools such as 3D ultrasonography or fetal MRI have been suggested. A study by Pashaj et al showed that 3D ultrasonography is helpful in the diagnosis of ACC [27]. Recently, several studies demonstrated the usefulness of fetal MRI to improve the sensitivity of the ACC diagnosis and to affirm associated anomalies [28,29]. Therefore, fetal MRI is recommended when necessary. In our study population, fetal MRI was performed for only 16% during the perinatal period. This low rate of fetal MRI performed in our center may reflect the specific laws of Korea, which prohibit abortion solely for fetal indications.
One-third of ACC cases are isolated ACC and the other two-thirds are non-isolated ACC [25]. In our study of 56 patients, 51.8% were considered to have isolated ACC and 48.2% were considered to have non-isolated ACC prenatally. Postnatally, 57% (4/7 cases) in this study had isolated ACC. However, this result might have been affected by selection bias, because these cases were found in patients who had been prenatally suspected to have isolated ACC and were followed-up after delivery.
The limitations of our study include the high rate of follow-up loss and insufficiency of long-term follow-up. There were 37 fetuses with unknown results. Data regarding the results for these patients could not be obtained for 14; the remaining 23 did not return to the original centers from which they were referred, and they were confirmed to be follow-up losses. There is a possibility that these patients underwent delivery in referred hospitals or other locations other than our center, but there is a high possibility that the majority chose termination. Therefore, adequate counseling regarding ACC is necessary to reduce the termination rate. Also, long-term follow-up at least until the age of beginning school [30] is necessary because there is a possibility that some neurodevelopmental delay may develop with time; the current follow-up duration is too short. In addition, large numbers of children with isolated ACC are needed for future studies. The incidence of ACC is less than 1%; therefore, multicenter studies of ACC and regular follow-ups conducted through consultation with pediatrics, neurology, or rehabilitation medicine departments are essential. Future studies will be meaningful for determining the prognosis of ACC and will be helpful for counseling patients.
It is noteworthy that we also supplemented the neurodevelopmental outcome of postnatal isolated ACC to partially overcome the limitation of small number in our study population. Considering that outcome of postnatally diagnosed ACCs could be comparatively unfavorable to prenatally diagnosed ACCs as they visit the hospital due to the presentation of symptoms, the findings that 55.6% and 75% of isolated ACC (postnatally and prenatally, respectively) showed normal neurodevelopmental outcome may be in accordance each other.
In summary, we demonstrated that neurodevelopmental outcomes for those with isolated ACC are favorable. However, we found very few studies on ACC in our country. A recent article from the perspective of rehabilitation investigated the neurodevelopmental outcomes of corpus callosal anomaly in Korea, but this study also included hypoplasia of corpus callosum as well as ACC [31]. Although limited in number, our single-center study has modest implications regarding neurodevelopmental outcomes of isolated ACC in Korea. We believe this clinical information is helpful for properly counseling these patients.

Notes

Conflict of interest: No potential conflict of interest relevant to this article was reported.

References

1. Paul LK, Brown WS, Adolphs R, Tyszka JM, Richards LJ, Mukherjee P, et al. Agenesis of the corpus callosum: genetic, developmental and functional aspects of connectivity. Nat Rev Neurosci 2007;8:287-299. PMID: 17375041.
crossref pmid
2. Engels AC, Joyeux L, Brantner C, De Keersmaecker B, De Catte L, Baud D, et al. Sonographic detection of central nervous system defects in the first trimester of pregnancy. Prenat Diagn 2016;36:266-273. PMID: 26732542.
crossref pmid
3. Grogono JL. Children with agenesis of the corpus callosum. Dev Med Child Neurol 1968;10:613-616. PMID: 5304353.
crossref pmid
4. d'Ercole C, Girard N, Cravello L, Boubli L, Potier A, Raybaud C, et al. Prenatal diagnosis of fetal corpus callosum agenesis by ultrasonography and magnetic resonance imaging. Prenat Diagn 1998;18:247-253. PMID: 9556041.
crossref pmid
5. Jeret JS, Serur D, Wisniewski K, Fisch C. Frequency of agenesis of the corpus callosum in the developmentally disabled population as determined by computerized tomography. Pediatr Neurosci 1985-1986;12:101-103.
crossref
6. Pilu G, Sandri F, Perolo A, Pittalis MC, Grisolia G, Cocchi G, et al. Sonography of fetal agenesis of the corpus callosum: a survey of 35 cases. Ultrasound Obstet Gynecol 1993;3:318-329. PMID: 12797254.
crossref pmid
7. Volpe P, Paladini D, Resta M, Stanziano A, Salvatore M, Quarantelli M, et al. Characteristics, associations and outcome of partial agenesis of the corpus callosum in the fetus. Ultrasound Obstet Gynecol 2006;27:509-516. PMID: 16619387.
crossref pmid
8. Moutard ML, Kieffer V, Feingold J, Lewin F, Baron JM, Adamsbaum C, et al. Isolated corpus callosum agenesis: a ten-year follow-up after prenatal diagnosis (how are the children without corpus callosum at 10 years of age?). Prenat Diagn 2012;32:277-283. PMID: 22430728.
crossref pmid
9. Hetts SW, Sherr EH, Chao S, Gobuty S, Barkovich AJ. Anomalies of the corpus callosum: an MR analysis of the phenotypic spectrum of associated malformations. AJR Am J Roentgenol 2006;187:1343-1348. PMID: 17056927.
crossref pmid
10. Tang PH, Bartha AI, Norton ME, Barkovich AJ, Sherr EH, Glenn OA. Agenesis of the corpus callosum: an MR imaging analysis of associated abnormalities in the fetus. AJNR Am J Neuroradiol 2009;30:257-263. PMID: 18988682.
crossref pmid pmc
11. Comstock CH, Culp D, Gonzalez J, Boal DB. Agenesis of the corpus callosum in the fetus: its evolution and significance. J Ultrasound Med 1985;4:613-616. PMID: 3908710.
crossref pmid
12. Shevell MI. Clinical and diagnostic profile of agenesis of the corpus callosum. J Child Neurol 2002;17:896-900. PMID: 12593462.
crossref pmid
13. Noguchi R, Abe K, Hamada H, Ogura T, Obata M, Miyazono Y, et al. Outcomes of patients with prenatally diagnosed agenesis of the corpus callosum in conjunction with ventriculomegaly. Arch Gynecol Obstet 2014;290:237-242. PMID: 24622935.
crossref pmid
14. Gupta JK, Lilford RJ. Assessment and management of fetal agenesis of the corpus callosum. Prenat Diagn 1995;15:301-312. PMID: 7617572.
crossref pmid
15. Vergani P, Ghidini A, Strobelt N, Locatelli A, Mariani S, Bertalero C, et al. Prognostic indicators in the prenatal diagnosis of agenesis of corpus callosum. Am J Obstet Gynecol 1994;170:753-758. PMID: 8141196.
crossref pmid
16. Mangione R, Fries N, Godard P, Capron C, Mirlesse V, Lacombe D, et al. Neurodevelopmental outcome following prenatal diagnosis of an isolated anomaly of the corpus callosum. Ultrasound Obstet Gynecol 2011;37:290-295. PMID: 21337654.
crossref pmid
17. Francesco P, Maria-Edgarda B, Giovanni P, Dandolo G, Giulio B. Prenatal diagnosis of agenesis of corpus callosum: what is the neurodevelopmental outcome? Pediatr Int 2006;48:298-304. PMID: 16732799.
crossref pmid
18. Li Y, Estroff JA, Khwaja O, Mehta TS, Poussaint TY, Robson CD, et al. Callosal dysgenesis in fetuses with ventriculomegaly: levels of agreement between imaging modalities and postnatal outcome. Ultrasound Obstet Gynecol 2012;40:522-529. PMID: 22262510.
crossref pmid pmc
19. Al-Hashim AH, Blaser S, Raybaud C, MacGregor D. Corpus callosum abnormalities: neuroradiological and clinical correlations. Dev Med Child Neurol 2016;58:475-484. PMID: 26661037.
crossref pmid
20. Sotiriadis A, Makrydimas G. Neurodevelopment after prenatal diagnosis of isolated agenesis of the corpus callosum: an integrative review. Am J Obstet Gynecol 2012;206:337.e1-337.e5. PMID: 22284958.
crossref pmid
21. Cignini P, D'Emidio L, Padula F, Girgenti A, Battistoni S, Vigna R, et al. The role of ultrasonography in the diagnosis of fetal isolated complete agenesis of the corpus callosum: a long-term prospective study. J Matern Fetal Neonatal Med 2010;23:1504-1509. PMID: 20230313.
crossref pmid
22. Isapof A, Kieffer V, Sacco S, Billette de Villemeur T, Gelot A, Garel C, et al. Impact of prenatal corpus callosum agenesis diagnosis on pregnancy outcome. Evaluation of 155 cases between 2000 and 2006. Arch Pediatr 2010;17:226-232. PMID: 20117919.
crossref pmid
23. Paladini D, Pastore G, Cavallaro A, Massaro M, Nappi C. Agenesis of the fetal corpus callosum: sonographic signs change with advancing gestational age. Ultrasound Obstet Gynecol 2013;42:687-690. PMID: 23671008.
crossref pmid
24. Ozyuncu O, Yazicioglu A, Turgal M. Antenatal diagnosis and outcome of agenesis of corpus callosum: a retrospective review of 33 cases. J Turk Ger Gynecol Assoc 2014;15:18-21. PMID: 24790511.
crossref pmid pmc
25. Ruland AM, Berg C, Gembruch U, Geipel A. Prenatal diagnosis of anomalies of the corpus callosum over a 13-year period. Ultraschall Med 2015 8 14 [Epub]. PMID: 10.1055/s-0035-1553665.

26. Rapp B, Perrotin F, Marret H, Sembely-Taveau C, Lansac J, Body G. Value of fetal cerebral magnetic resonance imaging for the prenatal diagnosis and prognosis of corpus callosum agenesis. J Gynecol Obstet Biol Reprod (Paris) 2002;31(2 Pt 1):173-182. PMID: 12016416.
pmid
27. Pashaj S, Merz E. Detection of fetal corpus callosum abnormalities by means of 3D ultrasound. Ultraschall Med 2016;37:185-194. PMID: 26529353.
crossref pmid
28. Craven I, Bradburn MJ, Griffiths PD. Antenatal diagnosis of agenesis of the corpus callosum. Clin Radiol 2015;70:248-253. PMID: 25498575.
crossref pmid
29. Glenn OA, Goldstein RB, Li KC, Young SJ, Norton ME, Busse RF, et al. Fetal magnetic resonance imaging in the evaluation of fetuses referred for sonographically suspected abnormalities of the corpus callosum. J Ultrasound Med 2005;24:791-804. PMID: 15914683.
crossref pmid
30. Moutard ML, Kieffer V, Feingold J, Kieffer F, Lewin F, Adamsbaum C, et al. Agenesis of corpus callosum: prenatal diagnosis and prognosis. Childs Nerv Syst 2003;19:471-476. PMID: 12845459.
crossref pmid
31. Kim YU, Park ES, Jung S, Suh M, Choi HS, Rha DW. Clinical features and associated abnormalities in children and adolescents with corpus callosal anomalies. Ann Rehabil Med 2014;38:138-143. PMID: 24639939.
crossref pmid pmc
Fig. 1

Ultrasonographic findings in a normal fetus (left) and with agenesis of corpus callosum (right). (A) Transventricular view. (B) Tear-drop sign. (C) Normal sagittal view. Corpus callosum can be seen. (D) Bull's head sign. Lateral displacement of anterior horns in the coronal plane. (E) Normal pericallosal artery. (F) Pericallosal artery is not visible on Doppler.

ogs-60-8-g001.jpg
Fig. 2

Clinical characteristics of 56 patients with prenatally suspected agenesis of corpus callosum (ACC) based on postnatal findings. SMC, Samsung Medical Center; CoA, coarctation of aorta; GMH, germinal matrix hemorrhage. *Isolated ACC was defined when there was no other anomaly on ultrasound or MRI based on prenatal or postnatal findings, respectively.

ogs-60-8-g002.jpg
Table 1

The characteristics of patients when prenatally diagnosed with ACC in our center (n=56)

Data presented as median (minimum-maximum) or number (%).

ACC, agenesis of corpus callosum; MRI, magnetic resonance imaging.

a)The gestational age at diagnosis was when the first ultrasonography gestational age was performed in our center and may not reflect the exact time of diagnosis. Five out of 56 cases were transferred to our center after gestational age of 34 weeks and 0 days, in which 4 of those cases delivered and are considered to have visited our center for the purpose of neonatal evaluation or neonatal intensive care unit care after delivery; b)One case is inv(9)(p12q13) which is normal variant.

Isolated ACC (n=29) Non-isolated ACC (n=27) P-value
Maternal age (yr) 30 (25-43) 32 (23-40) 0.036
Gestational age at diagnosisa) (wk) 25 (20-37) 22 (17-36) 0.007
Ultrasound findings
 Presence of ventriculomegaly 23 (79.3) 19 (70.4) 0.440
 Size of ventriculomegaly (mm) 16.3 (10.4-22.8) 12.6 (10.5-25.4) 0.069
 Presence of tear-drop sign 21 (72.4) 19 (70.4) 0.866
Chromosomal analysis 1.000
 Normal 6 (100) 7 (87.5)b)
 Abnormal 0 1 (12.5)
Prenatal brain MRI 6 (20.7) 4 (14.8) 0.566
Follow-up results 0.661
 Refer back 5 (17.2) 2 (7.4)
 Follow-up loss 12 (41.4) 11 (40.7)
 Unknown 7 (24.1) 7 (25.9)
 Delivery in our center 5 (17.2) 7 (25.9)
Table 2

Summary of characteristics and outcome in 12 cases with agenesis of corpus callosum delivered in our center

MRI, magnetic resonance imaging; iACC, isolated agenesis of corpus callosum; RO, rule out; MCM, mega cisterna-magna; SGA, small for gestational age; CoA, coarctation of aorta; IVH, intraventricular hemorrhage; GMH, germinal matrix hemorrhage.

Case Maternal age (yr) Gestational age at diagnosis (wk) Ventriculomegaly Chromosomal analysis Brain MRI Prenatally diagnosis Postnatally diagnosis Outcome
1 32 36+2 Present Not done Postnatally iACC iACC Intermittent exotropia, no delayed development (until 7 years) → follow-up loss
2 34 23+4 Present Normal Postnatally Non-iACC (R/O MCM) Non-iACC (lobar type holoprosencephaly) Delayed development (until 17 month) → follow-up loss
3 27 36+2 Present Not done Prenatally Non-iACC (MCM) iACC Transfer
4 25 24+1 Present Normal Prenatally & Postnatally iACC iACC No delayed development (until 19 month) → follow-up loss
5 32 24+2 Present Normal Not done Non-iACC (pyelectasis) Not available Termination
6 29 30+2 Present Normal Prenatally iACC iACC No delayed development (until 12
month) → follow-up loss
7 31 37+6 Present arr Xp11.22 (53,166,281-53,427,895)x1 Postnatally iACC Non-iACC (SGA, semilobar to lobar holoprosencephaly) Symptomatic localization‐related epilepsies (until now, for 29 month)
8 33 21+0 Present Normal Not done Non-iACC (CoA) CoA, hypospadias Follow-up (until now, for 27 month)
9 31 34+4 Present Normal Prenatally Non-iACC (RO right IVH) Cystic GMH, bilateral ventriculomegaly No delayed development (until 32 month) → observation
10 34 20+1 Absent Normal Not done Non-iACC (cleft lip) Non-iACC (cleft lip, Right inguinal hernia) Follow-up (until now, for 3 month)
11 39 21+2 Absent Normal Not done Non-iACC (posterior neck lymphangioma, bilateral pyelectasis, RO Dandy-Walker syndrome) Fetal hydrops Expired (2 days after birth)
12 31 20+6 Absent Normal Prenatally iACC Not available Termination
Table 3

Characteristics of delivered casea) in our center (n=10)

Data presented as median (minimum-maximum), number, or number (%).

NICU, neonatal intensive care unit.

a)Except termination case; b)Includes all 10 cases; c)Except 4 cases who transferred to our center just for delivery.

Variable Value
Maternal age (yr) 31.5 (25-39)
Gestational age at diagnosisb) (wk) 27 (20-37)
Gestational age at diagnosisc) (wk) 22 (20-30)
Ultrasound findings
 Presence of ventriculomegaly 8
 Presence of tear-drop sign 8
Chromosomal analysis 8
 Normal 7 (87.5)
Gestational age at delivered (wk) 36.5 (31-39)
Delivery mode
 Cesarean section 5 (50)
  Induction failure 1
  Previous cesarean section 1
  Fetal distress 2
  Breech position 1
 Vaginal delivery 5 (50)
Preterm delivery 5
Neonatal birth weight (g) 2,470 (960-3630)
NICU admission 4 (40)


ABOUT
ARTICLE & TOPICS
Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES
POLICY
FOR CONTRIBUTORS
Editorial Office
4th Floor, 36 Gangnam-daero 132-gil, Gangnam-gu, Seoul 06044, Korea.
Tel: +82-2-2266-7238    Fax: +82-2-3445-2440    E-mail: journal@ogscience.org                

Copyright © 2024 by Korean Society of Obstetrics and Gynecology.

Developed in M2PI

Close layer
prev next